TDOC Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of 0.11%. Teladoc Health, Inc.'s return on equity of -15.44% beat Astrana Health, Inc.'s return on equity of 1.85%.

Teladoc Health, Inc. has a consensus price target of $8.93, signalling upside risk potential of 63.89%. On the other hand Astrana Health, Inc. has an analysts' consensus of $36.8889 which suggests that it could grow by 62.22%. Given that Teladoc Health, Inc. has higher upside potential than Astrana Health, Inc., analysts believe Teladoc Health, Inc. is more attractive than Astrana Health, Inc..

Teladoc Health, Inc. has a beta of 2.040, which suggesting that the stock is 103.96% more volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Teladoc Health, Inc.'s net income of -$49.5M is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while Astrana Health, Inc.'s PE ratio is 119.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.38x versus 0.38x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of 9.58%. Teladoc Health, Inc.'s return on equity of -15.44% beat Cryo-Cell International, Inc.'s return on equity of --.

Teladoc Health, Inc. has a consensus price target of $8.93, signalling upside risk potential of 63.89%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 156.02%. Given that Cryo-Cell International, Inc. has higher upside potential than Teladoc Health, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Teladoc Health, Inc..

Teladoc Health, Inc. has a beta of 2.040, which suggesting that the stock is 103.96% more volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.12%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 19.58% to investors and pays a quarterly dividend of $0.15 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. Teladoc Health, Inc.'s net income of -$49.5M is lower than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.38x versus 0.85x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Evolent Health, Inc. has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of -4.35%. Teladoc Health, Inc.'s return on equity of -15.44% beat Evolent Health, Inc.'s return on equity of -13.6%.

Teladoc Health, Inc. has a consensus price target of $8.93, signalling upside risk potential of 63.89%. On the other hand Evolent Health, Inc. has an analysts' consensus of $9.60 which suggests that it could grow by 186.04%. Given that Evolent Health, Inc. has higher upside potential than Teladoc Health, Inc., analysts believe Evolent Health, Inc. is more attractive than Teladoc Health, Inc..

Teladoc Health, Inc. has a beta of 2.040, which suggesting that the stock is 103.96% more volatile than S&P 500. In comparison Evolent Health, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.427%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolent Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. Evolent Health, Inc. pays out 32.59% of its earnings as a dividend. Evolent Health, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are larger than Evolent Health, Inc. quarterly revenues of $479.5M. Teladoc Health, Inc.'s net income of -$49.5M is lower than Evolent Health, Inc.'s net income of -$20.9M. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while Evolent Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.38x versus 0.18x for Evolent Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

HCA Healthcare, Inc. has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of 11.09%. Teladoc Health, Inc.'s return on equity of -15.44% beat HCA Healthcare, Inc.'s return on equity of 3428.29%.

Teladoc Health, Inc. has a consensus price target of $8.93, signalling upside risk potential of 63.89%. On the other hand HCA Healthcare, Inc. has an analysts' consensus of $528.52 which suggests that it could grow by 8.05%. Given that Teladoc Health, Inc. has higher upside potential than HCA Healthcare, Inc., analysts believe Teladoc Health, Inc. is more attractive than HCA Healthcare, Inc..

Teladoc Health, Inc. has a beta of 2.040, which suggesting that the stock is 103.96% more volatile than S&P 500. In comparison HCA Healthcare, Inc. has a beta of 1.362, suggesting its more volatile than the S&P 500 by 36.191%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HCA Healthcare, Inc. offers a yield of 0.59% to investors and pays a quarterly dividend of $0.72 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. HCA Healthcare, Inc. pays out 10.17% of its earnings as a dividend. HCA Healthcare, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are smaller than HCA Healthcare, Inc. quarterly revenues of $19.5B. Teladoc Health, Inc.'s net income of -$49.5M is lower than HCA Healthcare, Inc.'s net income of $2.2B. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while HCA Healthcare, Inc.'s PE ratio is 17.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.38x versus 1.55x for HCA Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.